Aug. 30 (Bloomberg) -- Diagnosticos da America, Latin America’s biggest medical diagnostics company, gained the most in three months in Sao Paulo trading after agreeing to buy MD1 Diagnosticos SA for an undisclosed amount.
Dasa, as the company is known, surged 6.7 percent to 19.20 reais, the most since May 21. Rival Fleury SA fell 2.8 percent to 21.10 reais and the Bovespa benchmark index slipped 2 percent.
“There’s synergy and Dasa would be entering the high-income market, which isn’t its base focus,” said Cesar Mezomo, an equity analyst for consumer stocks at Sao Paulo-based Victoire Brasil Investimentos. “It’s good to keep up with Fleury and to improve its presence in Rio de Janeiro.”
Under the agreement, MD1 will have to secure control of Pro-Echo Cardiodata Servicos Medicos Ltda., Clinica de Ressonancia e Multi-Imagem Ltda., CDPI - Clinica de Diagnosticos por Imagem Ltda. and Laboratorios Medicos Dr. Sergio Franco Ltda., the statement said.
“But there haven’t been many details released, so we don’t know how much they are paying,” said Mezomo in a telephone interview.
Dasa also agreed to pay 88.5 million reais ($50.3 million) for a 10 percent stake in Pro-Echo, 28 percent in Clinica de Ressonancia e Multi-Imagem Ltda. and 16.5 percent in CDPI, the statement said.
Amil Participacoes SA, a Brazilian health insurance provider, fell 0.4 percent to 16.33 reais. OdontoPrev SA, Brazil’s largest provider of dental-care plans, dropped 2.4 percent to 18.50 reais.
To contact the reporter on this story: Alexander Ragir in Rio de Janeiro at email@example.com.
To contact the editor responsible for this story: David Papadopoulos at firstname.lastname@example.org